NCT06155110View on ClinicalTrials.gov

A Randomized, Single-blind, Controlled Clinical Study of Cardiomyopeptidin on Improving Ischemia-reperfusion Injury in Patients With Acute ST-segment Elevation Myocardial Infarction After Primary PCI

PHASE4CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

November 1, 2019

Primary Completion Date

March 1, 2025

Study Completion Date

May 1, 2025

Conditions
Cardiovascular Diseases
Interventions
DRUG

cardiomyopeptidin

cardiomyopeptidin intervention group will accept cardiomyopeptidin (Dalian Zhenao Pharmaceutical Co., Ltd., approval number: National Drug Approval No. H20052173, specification: 20 mg/tube) 3 mg/(kg·d)；

Trial Locations (1)

100853

Chinese People's Liberation Army General Hospital, Beijing

All Listed Sponsors
collaborator

Dalian Zhen-Ao Bio-Tech Co., Ltd.

INDUSTRY

lead

Chinese PLA General Hospital

OTHER

NCT06155110 - A Randomized, Single-blind, Controlled Clinical Study of Cardiomyopeptidin on Improving Ischemia-reperfusion Injury in Patients With Acute ST-segment Elevation Myocardial Infarction After Primary PCI | Biotech Hunter | Biotech Hunter